CirculoGene provides blood-based testing for detecting clinically significant tumor DNA/RNA alterations. The company uses a patented methodology for DNA yield and RNA preservation, employing next-generation sequencing and polymerase chain reaction instrumentation for DNA and RNA detection.

CirculoGene

Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. One tube, one week, complete results. Somatic + Germline; Blood + Tissue + Buccal; DNA + RNA + MSI + PD-L1. 

CONTACT
info@circulogene.com

For Asia Pacific inquiries,
please email AsiaPacfic@circulogene.com

For Middle Eastern inquiries,
please email Irem.Agin@circulogene.com.tr

CIRCULOGENE

Tumor markers play a crucial role in the diagnosis and management of cancer. At Circulogene, our TumorClear test uses next-generation sequencing to provide a detailed molecular profile of your tumor, including essential guideline and expert-recommended DNA mutations. This comprehensive analysis helps your physician tailor a treatment plan that is specifically designed for your unique cancer. Learn more about the significance of tumor markers and how they can influence your treatment at https://lnkd.in/exce_3h9

At Circulogene, we harness the power of advanced diagnostics technology to revolutionize healthcare. Our proprietary methodologies, including next-generation sequencing (NGS) and polymerase chain reaction (PCR), allow us to provide comprehensive and precise diagnostic results. By utilizing these state-of-the-art techniques, we offer unparalleled accuracy in detecting tumor DNA and RNA, enabling personalized treatment plans for our patients. Discover more about how we are leading the way in medical innovation at https://lnkd.in/exce_3h9

I recently heard from a friend that his parent had been diagnosed with stage 4 cancer. We are very lucky to live at a time when there are exceptional diagnostic tools, procedural tools, doctors/staff, treatment options and facilities available to treat patients with stage 4 cancer, improving outcomes and life expectancy.
Several years ago, when my father was battling his cancer, he would tell me he was going to win and beat this! We cheered him on as he fought the good fight and I knew it made a difference for him that we were all fighting at his side. It wasn’t enough, he lived for a year and 2 weeks after his diagnosis. As you might expect, i think about him often and wonder if he had current opinions available to him, would he still be alive?
There are many warriors out there who have a much better chance at winning today than my father did because there are many more weapons to use. I work in the cancer diagnostic industry and have met many exceptional people who are fighting cancer as physicians, nurses, program directors, and industry leaders. We are all working to provide the best options for each individual. 
I was missing my dad today and hoping my friend and his family can win. Im cheering for them as well.

#findacure
#cancersucks
#warriorlife

Why Circulogene? Complete, Accurate, and Timely Testing.

Dr. Walker is one of the most trusted professionals in the industry. Hear as he walks us thorugh the importance of liquid biposy testing for early detection.

Hear from Mike Mullen our founder, on "Why Circulogene".

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 26, 2024 11:36 AM	d9592ca0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 26, 2024 11:36 AM	c931abe1
translate crunchbase fundingrounds	general
peers	general	Aug 26, 2024 11:36 AM	aef6e555
news basic	general	Aug 26, 2024 11:36 AM	efbad15c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CIRC

COM:CIRCULOGENE

CirculoGene